Calliditas Therapeutics Ab CALT
We take great care to ensure that the data presented and summarized in this overview for Calliditas Therapeutics AB is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CALT
View all-
Crossmark Global Holdings, Inc.16.1KShares$644,6800.01% of portfolio
-
Advisors Preferred, LLC Rockville, MD2.02KShares$80,8800.01% of portfolio
-
Simplex Trading, LLC1.83KShares$73,0400.0% of portfolio
-
Rhumbline Advisers Boston, MA303Shares$12,1200.0% of portfolio
-
Missouri Trust & Investment CO Springfield, MO35Shares$1,4000.0% of portfolio
-
Nalls Sherbakoff Group, LLC Knoxville, TN18Shares$7200.0% of portfolio
Latest Institutional Activity in CALT
Top Purchases
Top Sells
About CALT
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Insider Transactions at CALT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|